Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
23 studies found for:    novocure
Show Display Options
Rank Status Study
1 Recruiting Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
Condition: Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Interventions: Device: NovoTTF-100M device;   Other: Best Standard of Care
2 Recruiting Effect of Tumor Treating Fields (TTFields) (150 kHz) as Second Line Treatment of Non-small Cell Lung Cancer (NSCLC) in Combination With PD-1 Inhibitors or Docetaxel (LUNAR)
Condition: Nonsmall Cell Lung Cancer
Interventions: Device: NovoTTF-100L;   Drug: PD1 inhibitors or docetaxel
3 Recruiting TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Conditions: Glioblastoma Multiforme;   Glioblastoma;   Malignant Glioma;   GBM
Interventions: Drug: Bevacizumab;   Device: Optune;   Other: Brain MRI;   Other: Quality of Life Questionnaires
4 Recruiting Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
Conditions: RECURRENT GLIOBLASTOMA;   Brain Tumor
Intervention: Device: Optune(NOVOTTF-100A)
5 Recruiting Tryptophan Metabolism in Human Brain Tumors
Condition: Glioblastoma
6 Active, not recruiting Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
Condition: Malignant Pleural Mesothelioma
Interventions: Device: NovoTTF-100L device;   Drug: Pemetrexed;   Drug: Cisplatin or Carboplatin
7 Active, not recruiting Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
Condition: Ovarian Carcinoma
Interventions: Device: NovoTTF-100L(O);   Drug: Paclitaxel
8 Active, not recruiting Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
Condition: Pancreatic Adenocarcinoma
Interventions: Device: NovoTTF-100L;   Drug: Gemcitabine;   Drug: nab-Paclitaxel
9 Active, not recruiting Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
Condition: 1-5 Brain Metastases From Non-Small Cell Lung Cancer
Interventions: Device: NovoTTF-100A device;   Other: Best Standard of Care
10 Completed Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device;   Drug: Temozolomide
11 Active, not recruiting NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Glioblastoma;   Brain Neoplasms
Interventions: Device: NovoTTF-100A;   Procedure: Quality-of-life assessment;   Genetic: Laboratory biomarker analysis
12 Terminated Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Condition: Recurrent Glioblastoma Multiforme
Intervention: Device: NovoTTF-100A
13 Completed NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   NSCLC
Intervention: Device: NovoTTF-100L
14 Completed Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
Condition: Recurrent Glioblastoma Multiforme
Intervention: Device: NovoTTF-100A
15 Active, not recruiting Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Condition: Brain Cancer
Intervention: Device: Optune (NovoTTF-100A)
16 Recruiting HUMC 1612: Optune NovoTTF-200A System
Condition: High Grade Glioma
Interventions: Device: Optune NovoTTF-200A System;   Drug: Bevacizumab;   Drug: Temozolomide
17 Recruiting Enhancing Optune Therapy With Targeted Craniectomy
Condition: Glioblastoma
Interventions: Device: Optune;   Procedure: Craniectomy
18 Recruiting Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioma;   Gliosarcoma
Interventions: Drug: Bevacizumab;   Device: TTFields
19 Recruiting A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
Condition: Glioma
Interventions: Device: NovoTTF-200A;   Drug: Temozolomide
20 Recruiting A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Condition: Cancer of Brain and Nervous System
Intervention: Device: bevacizumab, NovoTTF100A, temozolomide

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.